WBA INVESTOR DEADLINE: Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - Walgreens Boots Alliance, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and unlawful conduct regarding prescription medication dispensing [1][3][4] Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Klein v. Walgreens Boots Alliance, Inc., and covers stock purchases made between April 2, 2020, and January 16, 2025 [1] - Investors have until March 31, 2025, to seek appointment as lead plaintiff in the lawsuit [1] Allegations Against Walgreens - The lawsuit alleges that Walgreens made false statements and failed to disclose ongoing violations of federal laws related to prescription medication [3] - Specific allegations include the dispensing of unlawful prescriptions and seeking reimbursement from federal health care programs, which led to a significant drop in stock price following the announcement of a civil complaint by the U.S. Department of Justice [4] Impact on Stock Price - Following the DOJ's announcement on January 17, 2025, Walgreens' stock price fell by more than 12% over two trading sessions [4] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Walgreens stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases, significantly more than any other firm in the last four years [6]